Impact of Donor Hepatitis C Virus Infection Status on Death and Need for Liver Transplant in Hepatitis C Virus-Positive Kidney Transplant Recipients

被引:35
|
作者
Kucirka, Lauren M. [1 ]
Peters, Thomas G. [2 ]
Segev, Dorry L. [1 ,3 ]
机构
[1] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA
[2] Univ Florida, Coll Med, Dept Surg, Jacksonville, FL USA
[3] Johns Hopkins Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
关键词
Hepatitis C; kidney transplant; liver transplant; competing risks; RENAL-TRANSPLANTATION; SURVIVAL; DIALYSIS; RISK;
D O I
10.1053/j.ajkd.2012.03.015
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Only 29% of deceased donor kidney recipients with hepatitis C virus (HCV) receive HCV-positive (HCV+) kidneys. These kidneys are discarded 2.5 times more often than their HCV-negative (HCV-) counterparts, possibly due to the sense that an HCV+ kidney may adversely affect recipient liver function. The goals of this study were to characterize liver disease in HCV+ kidney recipients and compare rates of liver-related outcomes by kidney donor HCV status. Study Design: Observational cohort study. Setting & Participants: 6,250 patients with HCV who had a kidney transplant in 1995-2008 as captured in the United Network for Organ Sharing (UNOS) database. Liver-related outcomes were assessed by cross-linking with the liver waitlist and transplant data sets. Predictor: HCV status of transplanted kidney. Outcomes: Joining the liver waitlist, receiving a liver transplant, death. Measurements: Time to event. Results: Only 63 (1%) of HCV+ kidney recipients eventually joined the liver waitlist during the 13-year study period. Those who received HCV+ kidneys had a 2.6-fold higher hazard of joining the liver list (P < 0.001); however, the absolute difference in rate of listing between recipients of HCV- and HCV+ kidneys was <2%. This is consistent with findings of only 2% lower patient survival at 3 years in HCV+ patients receiving HCV+ versus HCV- kidneys. Limitations: We lacked data for HCV viral load and genotype of both HCV+ recipients and transplanted HCV+ kidneys. Conclusions: Because transplant with an HCV+ kidney may reduce waiting-time by more than a year for an HCV+ patient and there is a high risk of kidney waitlist mortality, a 2% increased rate of adverse liver outcomes and 2% increased rate of death at 3 years should not universally preclude the use of HCV+ kidneys when the intended recipient is also HCV+. Am J Kidney Dis. 60(1):112-120. (C) 2012 by the National Kidney Foundation, Inc.
引用
收藏
页码:112 / 120
页数:9
相关论文
共 50 条
  • [21] HEPATITIS-C VIRUS-INFECTION IN KIDNEY-TRANSPLANT RECIPIENTS
    VALERI, M
    PISANI, F
    DEPAOLIS, P
    PIAZZA, A
    TORLONE, N
    UTZERI, G
    ELLI, M
    TISONE, G
    ADORNO, D
    CASCIANI, CU
    TRANSPLANTATION PROCEEDINGS, 1993, 25 (03) : 2284 - 2285
  • [22] The prevalence and clinical significance of hepatitis C virus infection in kidney transplant recipients
    Yuri, T
    Yamaya, H
    Sakamoto, S
    Nakazawa, T
    Asaka, M
    Tomosugi, N
    Ishikawa, I
    Suzuki, K
    Tugawa, R
    JAPANESE JOURNAL OF TRANSPLANTATION, 1998, 33 (01) : 24 - 31
  • [23] HEPATITIS-C VIRUS-INFECTION IN KIDNEY-TRANSPLANT RECIPIENTS
    LAU, JYN
    DAVIS, GL
    BRUNSON, ME
    QIAN, KP
    LIN, HJ
    QUAN, S
    DINELLO, R
    POLITO, AJ
    SCORNIK, JC
    HEPATOLOGY, 1993, 18 (05) : 1027 - 1031
  • [24] Hepatitis C virus core antigen testing in liver and kidney transplant recipients
    Heidrich, B.
    Pischke, S.
    Helfritz, F. A.
    Mederacke, I.
    Kirschner, J.
    Schneider, J.
    Raupach, R.
    Jaeckel, E.
    Barg-Hock, H.
    Lehner, F.
    Klempnauer, J.
    von Hahn, T.
    Cornberg, M.
    Manns, M. P.
    Ciesek, S.
    Wedemeyer, H.
    JOURNAL OF VIRAL HEPATITIS, 2014, 21 (11) : 769 - 779
  • [25] Harmful long-term impact of hepatitis C virus infection in kidney transplant recipients
    Legendre, C
    Garrigue, V
    Le Bihan, C
    Mamzer-Bruneel, MF
    Chaix, ML
    Landais, P
    Kreis, H
    Pol, S
    TRANSPLANTATION, 1998, 65 (05) : 667 - 670
  • [26] Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients
    Gutierrez, Julio A.
    Carrion, Andres F.
    Avalos, Danny
    O'Brien, Christopher
    Martin, Paul
    Bhamidimarri, Kalyan Ram
    Peyton, Adam
    LIVER TRANSPLANTATION, 2015, 21 (06) : 823 - 830
  • [27] Kidney Transplantation from a Hepatitis C Virus-positive Donor to a Hepatitis C Virus-negative Recipient
    Kamalkiran, M.
    Ravikiran, V
    Shashidhar, C.
    Prasad, K. V. R.
    Yeldandi, V
    INDIAN JOURNAL OF NEPHROLOGY, 2018, 28 (06) : 488 - 489
  • [28] Daily interferon therapy for hepatitis C virus infection in liver transplant recipients
    Cotler, SJ
    Ganger, DR
    Kaur, S
    Rosenblate, H
    Jakate, S
    Sullivan, DG
    Ng, KW
    Gretch, DR
    Jensen, DM
    TRANSPLANTATION, 2001, 71 (02) : 261 - 266
  • [29] Oxidative Stress and Nutritional Factors in Hepatitis C Virus-Positive Liver Recipients, Controls, and Hepatitis C Virus-Positive Nontransplant Patients
    Madill, J.
    Arendt, B.
    Aghdassi, E.
    Chow, C.
    Guindi, M.
    Therapondos, G.
    Lilly, L.
    Allard, J.
    TRANSPLANTATION PROCEEDINGS, 2010, 42 (05) : 1744 - 1749
  • [30] Experience of Fibrosing Cholestatic Hepatitis With Hepatitis C Virus in Kidney Transplant Recipients
    Siddiqui, A. R.
    Abbas, Z.
    Luck, N. H.
    Hassan, S. M.
    Aziz, T.
    Mubarak, M.
    Naqvi, S. A.
    Rizvi, S. A. H.
    TRANSPLANTATION PROCEEDINGS, 2012, 44 (03) : 721 - 724